Patents Examined by Michael G. Hartley
  • Conjugate with target-finding ligand and use thereof
    Patent number: 9555122
    Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: January 31, 2017
    Assignee: ethris GmbH
    Inventors: Carsten Rudolph, Johannes-Peter Geiger
  • Compositions and methods for in vivo imaging of myelin in the peripheral nervous system
    Patent number: 9555130
    Abstract: A method of detecting and/or labeling myelin in an animal's peripheral nervous system tissue includes administering to the animal a fluorescent stilbenzene derivative and visualizing the animal's peripheral nervous system tissue using an in vivo imaging modality.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: January 31, 2017
    Assignee: Case Western Reserve University
    Inventors: Yanming Wang, Chunying Wu
  • Method for synthesizing radiopharmaceuticals using a cartridge
    Patent number: 9550704
    Abstract: The present invention relates to a method for synthesizing a radiopharmaceutical using a cartridge, which makes it possible to carry out several steps of reaction required for synthesizing a radiopharmaceutical in the cartridge filled with a polymer. A method for synthesizing a radiopharmaceutical according to the present invention enables each step's reaction to be carried out with the solution confined in the cartridge so as not to flow out, thus being simplified compared to the conventional methods for synthesizing radiopharmaceuticals, and expediting the synthesis thereof.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: January 24, 2017
    Assignee: FUTURECHEM CO., LTD.
    Inventors: Dae Yoon Chi, Byoung Se Lee, Jae Hak Lee, So Young Chu, Woon Jung Jung
  • Stabilized gold nanoparticle and contrast agent
    Patent number: 9549998
    Abstract: A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: January 24, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Vijaya Kattumuri, Kattesh V. Katti, Evan Boote, Raghuraman Kannan, Stan Casteel, Robert Churchill
  • Radiopharmaceutical composition
    Patent number: 9549999
    Abstract: The present invention provides a 99mTc-tetrofosmin radiopharmaceutical composition comprising tetrofosmin and a radioprotectant at a particular range of molar ratios. A kit and a multi-dose kit for the preparation of the radiopharmaceutical composition of the invention are also provided, as well as a process for the preparation of multiple unit patient doses of the radiopharmaceutical composition and a unit dose of the radiopharmaceutical composition.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: January 24, 2017
    Assignee: GE Healthcare Limited
    Inventors: Janne Veggeland, Grethe Karin Madsen, Stig Hemsted
  • Compositions, methods of synthesis and use of carbohydrate targeted agents
    Patent number: 9550001
    Abstract: The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R1?, R2? are each independently —OH or —O-alkyl; R1 is a hydrogen, a linker, or a ligand; R3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: January 24, 2017
    Assignee: RadioMedix Inc.
    Inventors: Izabela Tworowska, Jennifer Sims-Mourtada, Ebrahim S. Delpassand
  • Compositions, methods, and systems for the synthesis and use of imaging agents
    Patent number: 9550000
    Abstract: The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: January 24, 2017
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Ming Yu
  • Sustained release pheromone preparation targeting insect pest having carboxylic acid as pheromone substance
    Patent number: 9545102
    Abstract: Targeting an insect pest having a carboxylic acid compound as a pheromone substance, provided is a sustained release pheromone preparation enabling a high amount of pheromone to be released during the control period. More specifically, provided is a sustained release pheromone preparation, comprising: a carboxylic acid compound to be released, and an ethylene-vinyl acetate copolymer membrane through which the carboxylic acid compound can permeate, wherein the preparation is targeted for an insect pest having the carboxylic acid compound as a pheromone substance.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: January 17, 2017
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Tatsuya Fujii, Tatsuya Hojo, Naoki Ishibashi, Ryuichi Saguchi, Takehiko Fukumoto
  • Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
    Patent number: 9546186
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: January 17, 2017
    Assignee: STC.UNM
    Inventors: Jeffrey P. Norenberg, Richard S. Larson
  • Low-density magnesia-alumina-silica (MAS) microparticles for radiotherapy and/or radioimaging
    Patent number: 9539347
    Abstract: This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: January 10, 2017
    Assignee: MO-SCI CORPORATION
    Inventors: Delbert E. Day, Yiyong He
  • Method to improve the tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting
    Patent number: 9539345
    Abstract: Disclosed herein is a method of improving tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting, and the multivalent ligands for tumor diagnosis.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: January 10, 2017
    Assignees: Korea Research Institute of Bioscience and Biotechnology, National Cancer Center
    Inventors: Yoonkyung Kim, Ju Young Heo, June-key Chung, Young-Hwa Kim, Seok Ki Kim, Se Hun Kang
  • Radiotherapeutic particles and suspensions
    Patent number: 9539346
    Abstract: The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 10, 2017
    Assignee: Oncoinvent AS
    Inventors: Roy Hartvig Larsen, Sara Westrøm
  • Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women
    Patent number: 9533050
    Abstract: The invention relates to a sustained-release vaginal ring which includes meloxicam and an agent for modulating the release of the active principle, such as polyvinylpyrrolidone K-30, which releases the active principle over at least 90 days and which can be used as a continuous-use contraceptive in women. The vaginal ring preferably includes 5 wt % to 30 wt % of meloxicam, relation to total weight of the formulation.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: January 3, 2017
    Assignee: LABORATORIOS ANDROMACO S.A.
    Inventors: Shu-Chen Chen, Marianela del Carmen Beltran Apablaza
  • Method for purification of 225AC from irradiated 226RA-targets
    Patent number: 9534277
    Abstract: The present invention describes a method for purification of 225Ac from irradiated 226Ra-targets provided on a support, comprising a leaching treatment of the 226Ra-targets for leaching essentially the entirety of 225Ac and 226Ra with nitric or hydrochloric acid, followed by a first extraction chromatography for separating 225Ac from 226Ra and other Ra-isotops and a second extraction chromatography for separating 225Ac from 210Po and 210Pb. The finally purified 225Ac can be used to prepare compositions useful for pharmaceutical purposes.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: January 3, 2017
    Assignee: ACTINIUM PHARMACEUTICALS, INC.
    Inventors: Josue Manuel Moreno Bermudez, Andreas Turler, Richard Henkelmann, Eva Kabai, Ernst Huenges
  • Abuse resistant transmucosal drug delivery device
    Patent number: 9522188
    Abstract: The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: December 20, 2016
    Assignee: BioDelivery Sciences International, Inc.
    Inventors: Andrew Finn, Niraj Vasisht
  • Method for collecting metal-containing fullerene
    Patent number: 9522199
    Abstract: A method for recovering an endohedral metallofullerene comprises a complexation step of adding a Lewis acid comprising titanium halide or tin halide to a reaction solution formed by dissolving crude fullerenes in a solvent, thereby forming a complex of the endohedral metallofullerene and the Lewis acid, a filtering step of filtering the reaction solution to separate the complex, and a washing step of removing the Lewis acid from the complex to obtain the endohedral metallofullerene. The obtained endohedral metallofullerene is soluble in a solvent. This method provides a high recovery yield of the endohedral metallofullerene.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: December 20, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Kazuhiko Akiyama, Tatsuyuki Hamano, Hisanori Shinohara, Yusuke Nakanishi
  • Medical contrast agent made of microbubbles containing fluorescent gold nanoclusters
    Patent number: 9523032
    Abstract: A medical contrast agent made of microbubbles containing Au nanoclusters is provided. The shell of the microbubbles contains fluorescent Au nanocluster-albumin complex, and the core contains air or fluorocarbons. The method for preparing the microbubbles is also disclosed.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: December 20, 2016
    Assignee: CHUNG YUAN CHRISTIAN UNIVERSITY
    Inventors: Cheng-An J. Lin, Walter Hong-Shong Chang, Chih-Hsien Lee, Wen-Kai Chuang
  • Photodynamic diagnostic agent and photobleaching inhibitor
    Patent number: 9517267
    Abstract: The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: December 13, 2016
    Assignees: SBI Pharmaceuticals Co., Ltd., Tokyo Institute of Technology
    Inventors: Masahiro Ishizuka, Tohru Tanaka, Shun-ichiro Ogura, Takuya Ishii
  • Compound and photoacoustic imaging contrast medium containing the compound
    Patent number: 9517278
    Abstract: The present invention provides a photoacoustic imaging contrast medium which exhibits a high degree of accumulation into a tumor even when some extent of time has passed after performing administration and which facilitates an increase in the intensity of photoacoustic signal produced by the tumor. A compound produced by covalent-bonding of an organic dye which absorbs light in the near-infrared wavelength region and a PEG having a branch.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: December 13, 2016
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Atsushi Takahashi, Fumio Yamauchi, Masato Minami, Satoshi Ogawa, Kengo Kanazaki, Satoshi Yuasa
  • 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
    Patent number: 9517279
    Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 13, 2016
    Assignee: The McLean Hospital Corporation
    Inventors: John L. Neumeyer, Yu-Gui Si, Anna W. Sromek